What insurance policy changes affect code M87.08?

There are 8 tracked policy changes affecting code M87.08, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M87.08?

Payers that have issued tracked updates for code M87.08 include: Aetna.

How do I get notified when code M87.08 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M87.08. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M87.08?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

M87.08 Insurance Policy Changes

ICD-10 M87.08 is officially defined as "Idiopathic aseptic necrosis of bone, other site." code M87.08 is referenced in 8 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M87.08 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 4, 2026Medium impact
Neuralgia Inducing Cavitational Osteonecrosis (NICO) and Ultrasonograph Bone Densitometer to Detect NICO (CPB 0642, reviewed 2026-09-09)
Surgery for neuralgia inducing cavitational osteonecrosis (NICO) is considered experimental, investigational or unproven, including scraping of infected cavities and removal of root-canal-treated teeth. Rinsing the cavity with colloidal silver, chelation therapy with intravenous vitamin C, and bone graft replacement for NICO-related diagnoses are also considered experimental, investigational or unproven. Devices that image the jawbones to diagnose NICO or NICO-type conditions are considered experimental, investigational or unproven because there is no adequate scientific evidence to support their clinical value.
Aetna · Identified Oct 2, 2026Medium impact
Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2026-09-14)
Aetna clinical policy bulletin 0649 (reviewed September 14, 2026) considers extracorporeal shock-wave therapy medically necessary only for calcific tendinopathy of the shoulder that has lasted at least 6 months, has a calcium deposit of 1 cm or more, and has not responded to conservative care. It lists many other musculoskeletal, pain, wound and scar indications as experimental or not covered. The source gives a review date but no effective date, so confirm current applicability before changing workflows.
Aetna · Identified Sep 29, 2026Medium impact
Biochemical Markers of Bone Remodeling (CPB 0562, reviewed 2026-08-21)
Aetna considers measurements of bone turnover markers for evaluating fracture risk experimental, investigational, or unproven, including bone sialoprotein, cathepsin K, osteocalcin, osteoprotegerin, P1NP, RANKL, sclerostin, and CTX-1 and NTX-1 telopeptides. Aetna also considers plasma homocysteine for evaluating fracture risk, plasma leptin for osteoporosis screening, and serum or urinary collagen crosslinks or other bone remodeling markers for the screening, diagnosis, or management of osteoporosis experimental, investigational, or unproven. Measurement of bone-specific alkaline phosphatase as a diagnostic marker for children and adolescents with secondary osteoporosis, bone turnover markers for persons receiving serotonergic anti-depressants, and collagen crosslinks for bisphosphonate-induced jaw osteonecrosis, chronic kidney disease, or osteogenesis imperfecta are also experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Neuralgia Inducing Cavitational Osteonecrosis (NICO) and Ultrasonograph Bone Densitometer to Detect NICO (CPB 0642, reviewed 2025-12-15)
Aetna's Clinical Policy Bulletin 0642 considers surgery for neuralgia inducing cavitational osteonecrosis (NICO) related diagnoses experimental, investigational or unproven, including scraping of infected cavities and removal of root-canal-treated teeth. Other NICO therapies are also listed as experimental, investigational or unproven, namely rinsing the cavity with colloidal silver, chelation therapy, intravenous vitamin C and bone graft replacement. Devices that image the jawbones to diagnose NICO or NICO-type conditions are experimental, investigational or unproven because there is no adequate scientific evidence to support their clinical value, and the policy states that current evidence is insufficient to support NICO as a distinct, validated clinical entity.
Aetna · Identified Aug 14, 2026Medium impact
Pulsed Electromagnetic Stimulation (CPB 0175, reviewed 2026-06-23)
High frequency pulsed electromagnetic stimulation, also called therapeutic magnetic resonance, is considered experimental, investigational or unproven for all indications listed, including acute post-operative pain and edema, bone consolidation, cancer, chronic low back pain, osteoarthritis, osteoporosis, Parkinson's disease, soft tissue injuries, tendinopathy and wounds. Transcutaneous low frequency pulsed electromagnetic stimulation is considered experimental, investigational or unproven for chronic pain including low back pain, fibromyalgia, hand tremors in Parkinson's disease, osteoarthritis, multiple sclerosis spasticity, neuropathic pain and wounds. CPT 0766T and 0767T, and HCPCS E0761, G0295 and G0329, are listed as not covered for the indications in the policy, and intermittent pulsed electromagnetic stimulation for fracture healing is addressed in CPB 0343 Bone Growth Stimulators.
Aetna · Identified Aug 12, 2026Medium impact
Blood and Adipose Tissue Derived Products for Selected Indications (CPB 0784, reviewed 2025-11-19)
Clinical Policy Bulletin 0784 considers the following experimental, investigational, or unproven because their effectiveness has not been established: autologous blood injection and platelet-poor or platelet-rich plasma injection for all indications, plus specific listed uses of autologous platelet gel, adipose-tissue-derived stem cell injections, autologous fat injection and other blood-derived products. Listed uses include platelet-rich plasma for rotator cuff injuries, osteoarthritis and plantar fasciitis, autologous platelet gel after total knee arthroplasty and for diabetic foot ulcer, and autologous fat injection for carpometacarpal arthritis of the thumb and velopharyngeal insufficiency. The policy also lists CPT, HCPCS and ICD-10 codes as not covered for the indications it lists.
Aetna · Identified Aug 12, 2026Medium impact
Biochemical Markers of Bone Remodeling (CPB 0562, reviewed 2025-08-22)
Aetna considers measurement of bone turnover markers for evaluating fracture risk experimental, investigational, or unproven because their clinical value for this indication has not been established. The markers listed include bone sialoprotein, cathepsin K, osteocalcin, P1NP, CTX, sclerostin, osteoprotegerin, and RANKL. Aetna also considers experimental, investigational, or unproven the measurement of biochemical markers for diagnosis and monitoring of aseptic loosening or osteolysis in total joint arthroplasty, for osteoporosis screening, diagnosis, or management, plasma homocysteine for fracture risk, plasma leptin for osteoporosis screening, and serum microRNAs.
Aetna · Identified Aug 15, 2026Low impact
Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2025-10-02)
This is Aetna Clinical Policy Bulletin 0649, reviewed October 2, 2025 and first found by PolicyChanges in August 2026, so it is historical material and the current version should be confirmed before acting. Aetna covers extracorporeal shock-wave therapy only for calcific tendinopathy of the shoulder with a calcium deposit of at least 1 cm lasting 6 months or more after conservative care has failed, and lists dozens of other musculoskeletal, wound and medical uses as experimental, investigational or unproven.

Watch M87.08

Get one email when a payer policy names M87.08, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Neuralgia Inducing Cavitational Osteonecrosis (NICO) and Ultrasonograph Bone Densitometer to Detect NICO (CPB 0642, reviewed 2026-09-09)

Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2026-09-14)

Biochemical Markers of Bone Remodeling (CPB 0562, reviewed 2026-08-21)

Neuralgia Inducing Cavitational Osteonecrosis (NICO) and Ultrasonograph Bone Densitometer to Detect NICO (CPB 0642, reviewed 2025-12-15)

Pulsed Electromagnetic Stimulation (CPB 0175, reviewed 2026-06-23)

Blood and Adipose Tissue Derived Products for Selected Indications (CPB 0784, reviewed 2025-11-19)

Biochemical Markers of Bone Remodeling (CPB 0562, reviewed 2025-08-22)

Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2025-10-02)

What insurance policy changes affect code M87.08?

Which payers have updated policy for code M87.08?

How do I get notified when code M87.08 policy changes?

Why do payers change policies for code M87.08?